Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05092568
Other study ID # COVID-19
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 5, 2022
Est. completion date July 15, 2022

Study information

Verified date May 2022
Source Saglik Bilimleri Universitesi
Contact Ozge MD Ozdemir, MD
Phone 9005326384089
Email drozgeozde@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

comparison of general characteristics of patients diagnosed COVID-19 positive followed In service


Description:

After the explanation about the study is made, informed consent form will be obtained from the pregnant women who were hospitalized in the pandemic gynecology service (D block 10th floor pandemic obstetrics service) due to COVID-19 and who agreed to participate in the study. In our study, the clinical status of pregnant patients with COVID-19 positive test results, who were followed up and treated in the pandemic service in Basaksehir City Hospital, will be obtained by asking the patient about the symptoms and vaccination status in the patient follow-up form prepared in advance. Laboratory findings and imaging results ( CT/ anteroposterior X-ray) will be obtained from the recorded data.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date July 15, 2022
Est. primary completion date July 15, 2022
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: Pregnant patients positive COVID-19 test results followed up and treated in the pandemic service of Çam and Sakura City Hospital. Exclusion Criteria: no exclusion criteria -

Study Design


Locations

Country Name City State
Turkey Department of Obstetrics and Gynecology, Maternal-Fetal Medicine Unit, Basaksehir City Hospital, Hamidiye School of Medicine, University of Health Sciences, Basaksehir Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Saglik Bilimleri Universitesi

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Number of Participants diagnosed of polymerase chain reaction assay Positive COVID-19 followed In service Two months
Primary Number of vaccinated participants Vaccinated patients who were followed up in the service due to COVID-19 Two months
Primary Number of non-vaccinated Participants non-vaccinated patients who were followed up in the service due to COVID-19 Two months
Primary rate of non-vaccinated -vaccinated Participants rate of non-vaccinated- vaccinated Participants who were followed up in the service due to COVID-19 Two months
Primary rate of covid symptoms rate of covid common symptoms (cough, fever, shortness of breath ,sore throat ) in vaccinated and unvaccinated patients Two months
Primary rate of inflammatory parameters rate of lymphocyte and albumin levels , C-reactive protein (CRP), D-dimer, Ferritin, lactate dehydrogenase(LDH), neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and C-reactive protein albumin ratio (CAR) levels in vaccinated and unvaccinated patients Two months
See also
  Status Clinical Trial Phase
Recruiting NCT05091411 - Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells) Phase 3
Completed NCT05107375 - Clinical Study of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Combined With Influenza Vaccine Phase 3
Active, not recruiting NCT05128643 - Clinical Study on the Immune Program of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Phase 3
Completed NCT04988217 - Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) Phase 1/Phase 2
Completed NCT04579393 - Fostamatinib for Hospitalized Adults With COVID-19 Phase 2
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Completed NCT04646044 - A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Phase 1
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Completed NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed NCT06189040 - Immunogenicity After COVID-19 Vaccines in Adapted Schedules Phase 4
Recruiting NCT04401436 - COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Not yet recruiting NCT04395742 - 1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
Recruiting NCT04388631 - Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
Completed NCT05501288 - Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019 N/A
Active, not recruiting NCT05216471 - Identify Coronavirus Disease by Chest X-ray
Terminated NCT04672564 - Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients Phase 3
Completed NCT04967781 - Autoimmunity Contributes to the Severe Progression of COVID-19
Completed NCT04678830 - Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19 Phase 2
Completed NCT04497194 - Registry of COVID-19 Patients at AOUI Verona